Mittie Doyle sold $412k of AVTX
Chief Medical Officer at Avalo Therapeutics, Inc.. 25,492 shares at an average of $16.15, traded Mar 16, 2026, filed Mar 18, 2026.
Score components
- +15RoleOfficer
- +16Trade size$412k at market
- +20Share of holdings soldSold 88% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.7%, 3m +4.9%, 6m +12.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001918845-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +19,500 | $12.65 | $247k | 23,122 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Common Stock10b5-1 | +5,992 | $8.04 | $48k | 29,114 | Mar 18, 2026 |
| Mar 16, 2026 | SOpen-market sale Common Stock10b5-1 | -25,492 | $16.15 | $412k | 3,622 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -19,500 | $0.00 | $0 | 214,500 | Mar 18, 2026 |
| Mar 16, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,992 | $0.00 | $0 | 149,008 | Mar 18, 2026 |
Related signals
Other insiders at Avalo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 4Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $202k 12,394 shares | -24% | |
| 12Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $179k 10,185 shares | -20% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 47Moderate | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $1.5M 72,725 shares | -89% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $20k 1,000 shares | -2% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 37Weak | Avalo Therapeutics, Inc. | Jennifer Riley Chief Strategy Officer | $52k 2,655 shares | -7% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $20k 1,000 shares | -2% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $93k 4,654 shares | -8% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $26k 1,450 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.